Nanomedicine & Nanoparticle Drug Delivery

Nanomedicine & Nanoparticle Drug Delivery

1. Definition, scope & the regulatory size threshold

• Nanomedicine = a medicinal dosage form derived from nanotechnology — the engineering of materials in the nanometre size range whose physical, chemical, or biological properties differ fundamentally from the same material at conventional (bulk) scale (Shargel 8e Ch.28, p.679; Shargel 8e Ch.9, pp.1380–2).
• Nanotechnology (working pharmaceutical definition) = manufacture of materials usually <100–200 nm; nanoscale materials have altered surface area, magnetic, electrical/optical, structural and chemical/biological activity versus their larger counterparts (Shargel 8e Ch.9, p.1381).
• FDA two-parameter test for whether a product "involves nanotechnology" (Shargel 8e Ch.28, pp.687–9):
  • (1) engineered to have at least one external dimension, internal structure, or surface structure in the nanoscale range ≈ 1–100 nm; OR
  • (2) engineered to exhibit properties/phenomena (physical, chemical, biological) attributable to its dimension(s) even outside the strict nanoscale, up to 1 µm (1000 nm).
• Key regulatory stance: the FDA has NOT created a separate framework for nanomedicines — the existing framework is held to be flexible/robust enough; nanomedicines must meet the same quality, safety, and efficacy standards as non-nanomaterial medicines (Shargel 8e Ch.28, pp.687–9).
• Nanomedicines are classed as complex drug products — which is why generic ("nanosimilar") versions of most nanomedicines have not been approved despite product-specific FDA guidances existing (Shargel 8e Ch.28, p.696).
• Why nanoscale matters pharmacologically — nanomedicines have a complex in-vivo transport mechanism not seen with conventional dosage forms: opsonization & mononuclear phagocyte (reticuloendothelial) clearance, enhanced permeability and retention (EPR), lymphatic transport, cellular recognition/internalization, enzymatic degradation, physical modulation (Shargel 8e Ch.28, pp.680–2).
• Therapeutic value proposition: improve dissolution and bioavailability of poorly water-soluble drugs, achieve drug targeting, and increase retention at the diseased organ/tissue (Shargel 8e Ch.28, p.683).
• Conceptual lineage — modern targeted nanocarriers operationalise Paul Ehrlich's 1900 "magic bullet" idea: a compound that selectively hits the disease-causing target without harming host cells (Shargel 8e Ch.10, pp.892–6).

Conventional-vs-novel baseline (Indian-exam framing). KDT contrasts these nanocarriers/targeted devices against conventional sustained-release approaches — coated/spansule oral SR, depot parenteral (benzathine penicillin, lente insulin, oily depot progestins, pellet/silastic/biodegradable implants), and transdermal patches (e.g. GTN) — which prolong action but are not target-selective (KDT 8e Ch.3, pp.42–4; KDT 8e Ch.1, supporting).